News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Daily News Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019 Yael L. Maxwell December 20, 2019
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2019 Todd Neale October 31, 2019
News Daily News Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes L.A. McKeown October 21, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2019 Shelley Wood October 01, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2018 Shelley Wood November 30, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018